Previous 10 | Next 10 |
AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the participation of its senior management in sessions at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). These include sessions on a...
AVROBIO (NASDAQ: AVRO ) initiated with Buy rating at Janney Montgomery Scott. More news on: AVROBIO, Inc., Amicus Therapeutics, Inc., Celgene Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
AVROBIO (NASDAQ: AVRO ): Q4 GAAP EPS of -$0.67 misses by $0.11 . More news on: AVROBIO, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Recruitment completed in investigator-sponsored Phase 1 Fabry study Phase 1 and Phase 2 clinical data updates for AVR-RD-01 in Fabry disease reported at WORLDSymposium 2019 Clinical trials in Gaucher and cystinosis expected to start in 2019 Introduced plato™ platform f...
AVROBIO, Inc . (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that the Company will present at the Cowen and Company 39 th Annual Health Care Conference on Wednesday, March 13, 2019, at 8:40 a.m. ET at the Marriott Copley Place i...
Gainers: China Internet Nationwide Financial Services (NASDAQ: CIFS ) +137% . Spark Therapeutics (NASDAQ: ONCE ) +120% . Clementia Pharmaceuticals (NASDAQ: CMTA ) +74% . uniQure N.V. (NASDAQ: QURE ) +30% . Titan Pharmaceuticals (NASDAQ: TTNP ) +27% . CRISPR Therapeutics AG (NASD...
The following slide deck was published by AVROBIO in conjunction with this Read more ...
AVROBIO ( AVRO +1% ) announces updated data from two clinical trials evaluating gene therapy AVR-RD-01 in Fabry patients. The results are being presented at the WORLD Symposium in Orlando, FL. More news on: AVROBIO, Healthcare stocks news, Stocks on the move, Read more ...
All patients with reported data exhibit AGA enzyme activity above the diagnostic range for males with classic Fabry disease after receiving AVR-RD-01, including at 22 months for Patient 1 in the Phase 1 study Impact of gene therapy on substrate and metabolite levels observed both in pa...
Noteworthy events during the week of February 3 - 9 for healthcare investors. More news on: AVROBIO, Amicus Therapeutics, Inc., Protalix BioTherapeutics, Inc, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-20 09:02:05 ET AvroBio Inc (AVRO) announced stock split at a ratio of 1-for-12 on 2024-06-21 ... Full story available on KlickAnalytics.com
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...